Natural history and prognostic factors for chronic hepatitis type B.

G Fattovich, L Brollo, G Giustina, F Noventa, P Pontisso, A Alberti, G Realdi, A Ruol

Istituto di Medicina Clinica, Clinica Medica 2, Università di Padova, Italy.

One hundred and five hepatitis B surface antigen (HBsAg) positive patients presenting with chronic persistent hepatitis (n = 46) or chronic active hepatitis without cirrhosis (n = 59) were followed longitudinally for one to 16 years (mean 5.5 years) and underwent follow up biopsy. During a mean histological follow up of 3.7 years, active cirrhosis developed in 21 (20%) patients one to 13 years after entry to the study with a calculated annual incidence of 5.9%. The probability of evolution to cirrhosis was significantly higher in patients with chronic active hepatitis and bridging hepatic necrosis than in those with moderate chronic active hepatitis or chronic persistent hepatitis (p less than 0.0001). Cox multiple regression analysis showed that the following three variables independently implied poor prognosis: older age, presence of bridging hepatic necrosis, and persistence of hepatitis B virus DNA in serum (p less than 0.0001). These findings indicate that patients with severe chronic active hepatitis and persistent hepatitis B virus replication are at very high risk of rapid progression to cirrhosis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., Naoumov, N. V., Di Bisceglie, A. M., Zeuzem, S., Moon, Y. M., Goodman, Z., Chao, G., Constance, B. F., Brown, N. A., the Globe Study Group, (2007). Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. NEJM 357: 2576-2588 [Abstract] [Full Text]  
• Pungpapong, S., Kim, W. R., Poterucha, J. J. (2007). Natural History of Hepatitis B Virus Infection: An Update for Clinicians. Mayo Clin Proc. 82: 967-975 [Abstract] [Full Text]  
• Lim, C. Y., Kowdley, K. V. (2007). Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother 60: 2-6 [Abstract] [Full Text]  
• Sung, J., Song, Y.-M., Choi, Y.-H., Ebrahim, S., Davey Smith, G. (2007). Hepatitis B Virus Seropositivity and the Risk of Stroke and Myocardial Infarction. Stroke 38: 1436-1441 [Abstract] [Full Text]  
• Larson, A. M., Curtis, J. R. (2006). Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life".. JAMA 295: 2168-2176 [Abstract] [Full Text]  
• Hui, C.-k., Lie, A., Au, W.-y., Leung, Y.-h., Ma, S.-y., Cheung, W. W. W., Zhang, H.-y., Chim, C.-s., Kwong, Y.-l., Liang, R., Lau, G. K. K. (2005). A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106: 464-469 [Abstract] [Full Text]  
• Kanwal, F., Gralnek, I. M., Martin, P., Dulai, G. S., Farid, M., Spiegel, B. M.R. (2005). Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis. ANN INTERN MED 142: 821-831 [Abstract] [Full Text]  
• Grieco, A, Pompili, M, Caminiti, G, Miele, L, Covino, M, Alfei, B, Rapaccini, G L, Gasbarrini, G (2005). Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418 [Abstract] [Full Text]  
• Liaw, Y. F., Sung, J. J.Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., Dixon, J. S., Gray, D. F., Sabbat, J., the Cirrhosis Asian Lamivudine Multicentre Study G, (2004). Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. NEJM 351: 1521-1531 [Abstract] [Full Text]  
• Adrain, A. L., Ramberan, H., Weaver, G. J. (2004). Evaluation of Common Liver Problems. J. Am. Podiatr. Med. Assoc. 94: 149-156 [Abstract] [Full Text]  
• Zhang, Y.-Y., Summers, J. (2004). Rapid Production of Neutralizing Antibody Leads to Transient Hepadnavirus Infection. J. Virol. 78: 1195-1201 [Abstract] [Full Text]  
• Papatheodoridis, G V, Papakonstantinou, E, Andrioti, E, Cholongitas, E, Petraki, K, Kontopoulou, I, Hadziyannis, S J (2003). Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52: 404-409 [Abstract] [Full Text]  
• ROBERTS, E A (2000). Why treat chronic hepatitis B in childhood with interferon alpha ?. Gut 46: 591a-593 [Full Text]  
• Devlin, J, O'Grady, J (1999). Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut 45: VI1-22 [Full Text]  
• Fendrick, A. M., Lee, J. H., LaBarge, C., Glick, H. A. (1999). Clinical and Economic Impact of a Combination Haemophilus influenzae and Hepatitis B Vaccine: Estimating Cost-effectiveness Using Decision Analysis. Arch Pediatr Adolesc Med 153: 126-136 [Abstract] [Full Text]  
• Margolis, H. S., Coleman, P. J., Brown, R. E., Mast, E. E., Sheingold, S. H., Arevalo, J. A. (1995). Prevention of Hepatitis B Virus Transmission by Immunization: An Economic Analysis of Current Recommendations. JAMA 274: 1201-1208 [Abstract]